The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look
Abstract
The authors evaluated interspecies scaling for the prediction of human clearance of 18 therapeutic monoclonal antibodies (mAbs). Human and monkey/chimpanzee data of 14 mAbs were classified based on the targeted antigens (soluble or membrane bound). Simple allometry and/or a time‐invariant method (elementary Dedrick plot) were performed. Results indicate that human clearance might be accurately predicted from monkey data for mAbs targeting soluble receptors or membrane‐bound receptors with limited tissue distribution using simplified allometry. The optimal exponents were estimated to be 0.85 or 0.90. If nonlinearity is anticipated at the human efficacious dose, pharmacokinetic parameters obtained at high doses in animals might not be sufficient for full pharmacokinetic characterization and prediction. Using prespecified criteria, including predicted human clearance (≤ or > 10 mL/d/kg), simplified allometric scaling might be helpful in predicting the effect of receptor‐mediated clearance for mAbs targeting membrane‐bound antigens. Furthermore, simplified allometry and an elementary Dedrick plot provide similar results in predicted clearance. Given the significant advantages offered by simplified allometry, it should be used when data are available from only 1 species. When reasonable data from ≥3 species are available, traditional allometry should be explored. Overall, clearance prediction is useful for human dose prediction in drug discovery and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The practice of projecting mAb PK in humans is well established,63, 64, 65, 66, 67”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [64]
In the citing paper
“two general approaches for antibodies with linear PK are commonly used.”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [64]
Citations
Cites
Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,930
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N. M., Guzzo, C. A., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,870
Papp, K. A., Langley, R. G. B., Lebwohl, M., Krueger, G. G., Szapary, P. O., Yeilding, N. M., Guzzo, C. A., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,358
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Gordon, M. S., Margolin, K. A., Talpaz, M., Sledge, G. W., Holmgren, E. B., Benjamin, R. S., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Monoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 741
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall’Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 648
Research works printed but not linked: 22
- Food and Drug Administration (FDA)., 2002, Guidance for Industry: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers
- Teorell T., 1937, Kinetics of distribution of substances administered to the body, Arch Intern Pharmacodyn, 57, 205
- Mahmood I., 2004, Pharmacokinetics in Drug Development: Clinical Study Design and Analysis, 423
- Tysabri (natalizumab) pharmacology review.www.fda.govcderfoinda2004125104s000Natalizumab.htm.
- Raptiva (efalizumab) pharmacology review.http:www.fda.govcderfoinda20031250750000RaptivaPharmrP1.pdf.
- 2005, Zenapax [package insert]
- 2008, Raptiva [package insert]
- 2008, Remicade [package insert]
- 2008, Erbitux [package insert]
- 2008, Avastin [package insert]
- 2008, Herceptin [package insert]
- 2008, Vectabix [package insert]
- 2008, Tysabri [package insert]
- Erbitux (cetuximab) pharmacology review.http:www.fda.govcderbiologicsnda125084ERBITUXBIOPHARMR.PDF.
- Zenapax (daclizumab) nonclinical pharmacology and toxicology review.http:www.fda.govcderbiologicsreviewdaclhof121097r2.pdf.
- Gabrielsson J, 2000, Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts & Applications
- DengR MortensenD PrabhuS et al.Prediction of human pharmacokinetics for monoclonal antibody. Presented at: AAPS National Biotechnology Conference;June 2427 2007; San Diego CA.
- 2008, Rituxan [package insert]
- Vozeh S, 1989, Pharmacokinetic Drug Data: Clinical Pharmacokinetic Drug Data Handbook
- Mahmood I., 2005, Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling
- 2009, Simponi [package insert]
- Herceptin (trastuzumab) clinical pharmacology review.http:www.fda.govcderbiologicsreviewtrasgen092598r3.pdf.
Cited by
Sorted by citations
Items 101–143 of 143
Marian, M., & Seghezzi, W. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394810-6.00004-6 · Cited by 4
Offman, E. M., & Edginton, A. N. (2016) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-016-0322-9 · Cited by 4
Schmidt, B. J., Pan, C., Vezina, H. E., Sun, H., Leipold, D. D., & Gupta, M. (2016) · Wiley eBooks · doi:10.1002/9781119060727.ch9 · Cited by 4
Singh, P., Tiwari, A., Abraham, A. K., & Zutshi, A. (2015) · CRC Press eBooks · doi:10.1201/b19023-7 · Cited by 3
Dose Finding in Single Dose Studies by Allometric Scaling
Lu, Z., Kaspera, R., Naritomi, Y., & Wang, T. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_3 · Cited by 3
Fonsi, M., Fulbert, J., Billat, P., Arbitrio, M., Tagliaferri, P., Tassone, P., & Martino, M. T. D. (2024) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2024.100197 · Cited by 3
Garzone, P. D., & Wang, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819869-8.00011-2 · Cited by 3
Béliveau, M., Rubets, I., Bojan, D., Hall, C. L., Toth, D., Kodihalli, S., & Kammanadiminti, S. J. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3097 · Cited by 3
Mager, D. E. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3_11 · Cited by 3
Biotherapeutic first-in-human dose selection: making use of preclinical markers
Johnson, D. E. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.5 · Cited by 3
Preclinical Studies to Enable First in Human Clinical Trials
Chopra, R., & Raynaud, F. I. (2020) · Springer eBooks · doi:10.1007/978-3-030-47682-3_3 · Cited by 3
Monoclonal Antibodies: From Structure to Therapeutic Application
Deng, R., Boswell, C. A., Putnam, W. S., Tang, M. T., Garg, A., Li, C., Chung, S., & Girish, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-00710-2_8 · Cited by 3
A systematic review of allometric scaling exponents for IgG mAbs
Rowland, S. P., Nixon, E., Mohan, K., Wang, Q., & Yates, J. W. T. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2383925 · Cited by 2
Fan, X., Cao, K., Wu, X., & Yan, X. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.00805-25 · Cited by 2
A Quantitative Prediction Method for the Human Pharmacokinetics of Fc-Fusion Proteins
Yokoyama, M., Suzuki, E., Oitate, M., & Watanabe, N. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00845-5 · Cited by 2
Béliveau, M., Anderson, D. M., Barker, D., Kodihalli, S., Simard, É., Hall, C. L., & Richardson, J. S. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2620 · Cited by 2
Resting Energy Expenditure and the Clearance of Therapeutic Proteins in Pediatric Subjects
Lee, S. K. (2014) · Pharmacology · doi:10.1159/000362562 · Cited by 2
Prediction of Human Pharmacokineticsfor Protein‐Based Biologic Therapeutics
Han, C., & Mayer, C. L. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse543 · Cited by 2
Dose Finding in Single Dose Studies by Allometric Scaling
Lu, Z., Kaspera, R., Naritomi, Y., & Wang, T. (2017) · Springer eBooks · doi:10.1007/978-3-319-56637-5_3-1 · Cited by 1
Pharmacokinetics and Toxicokinetics in Drug Development
Licollari, A., & Bolger, G. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85704-8.00002-5 · Cited by 1
Tajiri, A., Matsumoto, S., Maeda, S., Soga, T., Kagiyama, K., Ikeda, H., Fukasawa, K., Miyata, A., & Kamimura, H. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2371921 · Cited by 1
Prediction of First-in-Human Dose of Chimeric Antigen Receptor-T (CAR-T) Cells from Mice
Mahmood, I. (2024) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-024-00918-z · Cited by 1
Nguyen, T., Chang, P. K. ‐., Panorchan, P., Sahin, U., Türeci, Ö., & Wu, S.-P. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01615 · Cited by 1
Chen, W., Wang, L., Ruan, Z., Lou, H., & Jiang, B. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.07.003 · Cited by 1
Garzone, P. D. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385471-1.00034-9 · Cited by 1
Toxicology and Adverse Drug Reactions
Snodin, D. J., & Suitters, A. (2011) · Wiley eBooks · doi:10.1002/9780470975053.ch3 · Cited by 1
Nonclinical Toxicological Support for Phase I Trials
Jones, D. R., & McBlane, J. W. (2014) · Wiley eBooks · doi:10.1002/9781118820186.ch8
Influence of the antibody variable domain on FcRn-dependent pharmacokinetics
Schoch, A. (2014) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.17528
Network biology in development of monoclonal antibody therapeutics
Ovacik, A. M. (2014) · Mathematical Biosciences · doi:10.1016/j.mbs.2014.09.004
Drug Development Strategies for Therapeutic Biologics: Industry Perspectives
Yuraszeck, T. M., & Gibbs, M. A. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse559
Wang, W., & Prueksaritanont, T. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse536
Therapeutic Antibodies—Protein Engineering to Influence ADME , PK , and Efficacy
Tachibana, T., Haraya, K., Iwayanagi, Y., & Igawa, T. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse538
[Progress on pharmacokinetic study of antibody-drug conjugates].
Guo, J., Gao, R., Quan, T.-F., Ling-yu, Z., Shi, B., Zhao, Y.-Y., Zhu, J., Li, M.-S., & Haizhi, B. (2015) · PubMed
Offman, E. M. (2016) · UWSpace (University of Waterloo)
Wang, H., Yang, Z., & Shi, R. (2019) · Wiley eBooks · doi:10.1002/9781119289234.ch4
PBPK MODELING OF BIOTHERAPEUTICS
Peters, S. A. (2021) · Wiley eBooks · doi:10.1002/9781119497813.ch8
Novel biopharmaceuticals: Pharmacokinetics, pharmacodynamics, and bioanalytics
Bosgra, S., & Gupta, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00013-4
Chow, T., Wardęcki, M., Storek, M., & Wong, N. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3692
Brillac, C., Sémiond, D., Oprea, C., Baruchel, A., Zwaan, C. M., & Nguyen, L. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04832-2
Gajewska, M., Kiffe, M., Calonder, C., Engelhardt, V., Miralbell, C. P., Gonzalo-Gil, E., Christianson, G. J., BETHUR, N., & Flora, A. (2026) · mAbs · doi:10.1080/19420862.2026.2668888
Tajiri, A., Matsumoto, S., Furukawa, N., Kagiyama, K., Ikeda, H., Fukasawa, K., & Takano, H. (2026) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.70035
Aoyama, M., Takanohashi, T., Ohba, F., & Mano, Y. (2026) · Future Science OA · doi:10.1080/20565623.2026.2696881
Metadata
- Authors
- Ling, J., Zhou, H., Jiao, Q., & Davis, H. M.
- Corresponding author
- Ling, Jie
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2009-12
- Volume
- 49
- Issue
- 12
- Pages
- 1382-1402
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2011077241
- Cited by
- 144
- References
- 68
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 15 · 2023: 5 · 2022: 7 · 2021: 10 · 2020: 6 · 2019: 8 · 2018: 6 · 2017: 9 · 2016: 10 · 2015: 14 · 2014: 11 · 2013: 11 · 2012: 10
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- interspecies scaling, therapeutic monoclonal antibodies, soluble receptor, cell surface receptors, receptor-mediated clearance
- MeSH terms
- Animals, Antibodies, Monoclonal, Humans, Metabolic Clearance Rate, Species Specificity, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
